

Males vs females														
	Author	RR	country	region	City	n	publicati on date	Start	End	recruitment window	F U	study desing	clinical setting	Diagnostic modality
Infecti on	Zhu W	0,95	China	Anhui		116	10-mrt	24-jan	20-f eb	27		cohort	Hospital	PCR
	Liu R a	1,1	China	Hubei	Wuhan	4880	7-mrt	22-jan	14-f eb	23		cohort	Hospital	PCR
	Ai T	1,05	China	Hubei	Wuhan	1014	26-feb	6-jan	6-feb	31		cohort	Hospital	PCR
	Dong Y	1,03	China	multiple regions		2135	1-apr		8-feb			cohort	General population	PCR
	Chu J	0,86	China	Hubei	Wuhan	54	29-mrt	7-jan	11-f eb	35	3 5	cohort	Hospital	PCR
	Shen N	1,09	China	Hubei	Wuhan	5630	30-apr	22-jan	18-f eb	27	2 7	cohort	Hospital	PCR
	KDC Resp Team	1,95	South Korea			2370					4 6	cohort	General population	
	Long C	1,11	China	Hubei	Yichang	87	11-mrt	20-jan	8-feb	19		cohort	Hospital	laboratory tests , CT findings
severe														
	Guan W J a	0,99	China	Multiple regions		1096	28-feb	11-dec	29-jan	49	5 1	cohort	Hospital	PCR
	Gao Y	0,98	China	Anhui	Fuyang	43	13-mrt	23-jan	2-feb	10		cohort	Hospital	PCR
	Li K	1,33	China	Chongqing and Jinan		83	29-feb	1-jan	29-feb	29		cohort	Hospital	PCR
	Wan S	0,94	China	Northeast Chongqing		135	22-apr	23-jan	8-feb	16	1 6	cohort	Hospital	PCR
	Wu J	1,01	China	Jiangsu, Anhui		280	27-mrt	20-jan	19-feb	30	3 0	cohort	Hospital	PCR
	Shi Y	2,44	China	Zhejiang		487	18-mrt		17-feb			cohort	Hospital	
	Qin C	1,09	China	Hubei	Wuhan	452	12-mrt	10-jan	12-feb	33		cohort	Hospital	PCR
	Tian S	1,38	China		Beijing	262	27-feb	20-jan	10-feb	21	2 1	cohort	Hospital	PCR
	Zhang J a	1,28	China	Hubei	Wuhan	140	18-feb	16-jan	3-feb	18		cohort	Hospital	PCR
	Qian GQ	1,82	China	Zhejiang		91	17-mrt	20-jan	11-feb	22	2 7	cohort	Hospital	PCR
	Zhang G a	1,51	China	Hubei	Wuhan	95	26-mrt	16-jan	25-feb	40	4 6	cohort	Hospital	PCR

	Wu C	1,43	China	Wuhan		201	13-mrt	25-dec	26-jan	32	5 0	cohort	Hospital	PCR
	Chen Q	0,96	China	Zhejiang	Taizhou	145	28-apr	1-jan	11-mrt	70	7 0	cohort	Hospital	PCR
	Liu Y	1,05	China		Shanghai	221	28-mei					cohort	Hospital	PCR
	Chen T b	1,21	China	Hubei	Wuhan	203	7-apr	1-jan	10-feb	40	5 0	cohort	Hospital	PCR
	Colaneri M	1,86	Italy	North Italy		44	23-apr	21-feb	28-feb	7	1 2	cohort	Hospital	PCR
	Chu J	1,15	China	Wuhan		54	29-mrt	7-jan	11-feb	35		cohort	Hospital	PCR
	Wang X	1,52	China	Wuhan	Fangcang	1012	27-mrt	7-feb	12-feb	5	1 5	cohort	Hospital	PCR
	Zhao X Y	0,75	China	Jingzhou		91	29-apr	16-jan	10-feb	25	2 5	cohort	Hospital	PCR
	Wang L b	1,01	China	hubei	Wuhan	116	31-mrt	14-jan	13-feb	30	3 0	cohort	Hospital	PCR
	Zhu Z	0,71	China	Zhejiang	Ningbo	127	17-apr	23-jan	20-feb	28	2 8	cohort	Hospital	PCR
	Zheng F	0,89	China		Changsha	161		17-jan	7-feb	21	2 1	cohort	Hospital	PCR
	Zhang G b	1,83	China	Hubei		221	5-apr	2-jan	10-feb	39	4 4	cohort	Hospital	PCR
	Chen G	2,35	China	Hubei	Wuhan	21	27-mrt	20-dec	27-jan	38	3 8	cohort	Hospital	PCR
	Wang R	1,35	China	Anhui	Fuyang	125	24-mrt	20-jan	8-feb	19	2 9	cohort	Hospital	PCR
	Zhang J c	1,07	China	Hubei	Wuhan	663	15-apr	11-jan	6-feb	26		cohort	Hospital	PCR
	Chen X	2,38	China	Hubei	Wuhan	48	17-apr	1-feb	19-feb	18	1 8	cohort	Hospital	PCR
	Zhang R	0,97	China	Hubei	Wuhan	120	1-apr	10-jan	10-feb	31	3 1	cohort	Hospital	PCR
	Wei J F	1,28	China	Sichuan		103	6-apr	16-jan	10-mrt	54		cohort	Hospital	PCR
	Liu R b	0,99	China	Hubei		119	31-mrt	31-jan	26-feb	26	2 6	cohort	Hospital	PCR
	Lyu P	0,98	China	Zhengzhou		51	17-apr	15-jan	24-feb	40	4 0	cohort	Hospital	PCR
	Pei G	1,29	China	Hubei	Wuhan	333	12-apr	28-jan	9-feb	12	2 6	cohort	Hospital	PCR
	Yu X b	2,02	China	Zhejiang		92	23-apr	19-jan	19-mrt	60	5 6	cohort	Hospital	PCR
	Zheng S	1,28	China	Zhejiang		96	6-apr	19-jan	15-feb	27	2 7	cohort	Hospital	PCR

	Long L	1,75	China	Hubei	Jingzhou city and Xiangyang city	301	20-apr	16-jan	24-feb	39	4 5	cohort	Hospital	PCR
ICU														
	Huang C	2,02	China	Hubei	Wuhan	41	24-jan	16-dec	2-jan	17		cohort	Hospital	PCR
	Wang D a	1,32	China		Wuhan	138	7-feb	1-jan	28-jan	27	3 3	cohort	Hospital	PCR
	Bingwen E F	1,62	Singapore			67	3-mrt	23-jan	28-feb	36		cohort	Hospital	PCR
	Zhang G a	1,41	China	Hubei	Wuhan	95	26-mrt	16-jan	25-feb	40	4 6	cohort	Hospital	PCR
	Kalligeros M	1,23	US	Rhode Island		103	30-apr	17-feb	5-apr	48	4 8	cohort	Hospital	PCR
	Wei J F	1,38	China	Sichuan		103	6-apr	16-jan	10-mrt	54		cohort	Hospital	PCR
	Myers L C	1,48	US	California		377	24-apr	1-mrt	31-mrt	30	3 9	cohort	Hospital	PCR
	Lyu P	0,55	China	Henan	Zhengzhou	51	17-apr	15-jan	24-feb	40	4 0	cohort	Hospital	PCR
	Rieg S	2,12	Germany		Freiburg	115	28-apr	25-feb	31-mrt	35	3 5	cohort	Hospital	PCR
	Cao J	1,85	China	Hubei	Wuhan	102	2-mrt	3-jan	1-feb	29	4 3	cohort	Hospital	PCR
	Long L	2,24	China	Hubei	Jingzhou city and Xiangyang city	301	20-apr	16-jan	24-feb	39	4 5	cohort	Hospital	PCR
death														
	Tang N	2,78	China	Hubei	Wuhan	183	18-feb	1-jan	3-feb	33	4 3	cohort	Hospital	PCR
	Tian S	2,13	China		Beijing	262	27-feb	20-jan	10-feb	21	2 1	cohort	Hospital	PCR
	Wu C	1,1	China	Hubei	Wuhan	201	13-mrt	25-dec	26-jan	32	5 0	cohort	Hospital	PCR
	Chen T b	4,84	China	Hubei	Wuhan	203	7-apr	1-jan	10-feb	40	5 0	cohort	Hospital	PCR
	Meng Y	1,56	China	Hubei	Wuhan	168	28-apr	16-jan	4-feb	19	6 4	cohort	Hospital	PCR
	Nikpouraghda m	1,2	Iran		Teheran	2968	19-apr	19-feb	15-apr	56	7 3	cohort	Hospital	PCR
	Richardson	1,03	US	New York		5700	22-apr	1-mrt	4-apr	34	3 4	cohort	Hospital	PCR
	Yan, Y	1,65	China	Hubei	Wuhan	193	6-apr	10-jan	24-feb	45		cohort	Hospital	PCR

Xu B	1,26	China	Hubei	Wuhan	187	13-apr	26-dec	1-mrt	66	6	cohort	Hospital	PCR
Zhang J c	1,6	China	Hubei	Wuhan	663	15-apr	11-jan	6-feb	26		cohort	Hospital	PCR
Du R H	0,77	China	Hubei	Wuhan	179	7-mei	25-dec	7-feb	44		cohort	Hospital	
Yang R	5,15	China	Hubei	Wuhan	212	24-apr	11-jan	16-mrt	65	6	cohort	Hospital	PCR
Chen R	2,69	China			1578	15-apr					cohort	Hospital	PCR
Tomlins J	0,88	UK		Bristol	95	30-apr	10-mrt	20-mrt	10	2	cohort	Hospital	

Males vs females					NOS								
Author	% comorbidities	% males	mean age	% BMI > 25	Case definition	Case representativeness	Control selection	control definition	exposure ascertainment	comparable ascertainment	non response rate	Overall quality	
Infection													
Zhu W			56	40	23	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	9	
Liu R a			46			Acceptable	Acceptable	Acceptable	Not acceptable	Acceptable	NA	7	
Ai T			46	51		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	9	
Dong Y			57	7		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Unknown	8	
Chu J			67	54		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	acceptable	9	
Shen N			47	49		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	acceptable	9	
KDC Resp Team			45			Not Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	7	
Long C			53			Acceptable	Not acceptable	Acceptable	Not acceptable	Acceptable	NA	6	
Severe													
Guan W J a	24	58	47		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	9	
Gao Y		61	43		Unknown	Acceptable	Acceptable	Acceptable	Unknown	Acceptable	NA	6	
Li K	18	53	45		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	9	
Wan S	32	53	47		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	9	
Wu J		54	43		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	9	
Shi Y		53	46		Acceptable	Acceptable	Acceptable	Acceptable	Unknown	unknown	NA	5	
Qin C	44	51	58		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	acceptable	9	
Tian S		49	48		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	9	
Zhang J a	64	51	57		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	acceptable	8	
Qian GQ		41	50		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	9	
Zhang G a		56	49		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	9	

Wu C	33	64	51		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	9
Chen Q		55	48		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	9
Liu Y		52			Not acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	8
Chen T b	42	53	55		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	9
Colaneri M	64	64	60		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	8
Chu J		67	54		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	acceptable	9
Wang X	11	52	51		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	9
Zhao X Y	23	54	46		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	7
Wang L b	44	58	54		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	unknown	8
Zhu Z	41	35	51	24	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	9
Zheng F	21	50	45		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	9
Zhang G b	35	49	54		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	8
Chen G	33	81	61		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	7
Wang R	27	57	37		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	unknown	9
Zhang J c	37	48	56		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	9
Chen X		77	65		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	7
Zhang R	73	43	61		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	8
Wei J F		54	49		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	9
Liu R b		52			Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	6
Lyu P	33	56	54		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	6
Pei G		55	56		Acceptable	Not Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	8
Yu X b		62	55		Not acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	5
Zheng S		60	55		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	9
Long L		50	50		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	9
ICU												
Huang C	32	73	49		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	9
Wang D a	46	54	57		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	9
Bingwen E F		55	42		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	9
Zhang G a		56	49		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	9
Kalligeros M		61	60	81,6	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	8
Wei J F		54	49		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	9
Myers L C		56	61		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	9
Lyu P	33	57	54		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	6
Rieg S		63	56		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	8
Cao J	46	52	53	24	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	9
Long L		50	50		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	9

Death											
Tang N	41	54	54		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	8
Tian S		49	48		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	9
Wu C	33	64	51		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	9
Chen T b	42	53	55		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	9
Meng Y	34	51	57		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	8
Nikpouragh dam	11	66	56		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	9
Richardson	94	60	63		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	9
Yan, Y	49	59	63		Acceptable	not acceptable	Acceptable	Acceptable	Acceptable	NA	8
Xu B		55	61		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	9
Zhang J c	37	48	56		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	9
Du R H		54	58		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	9
Yang R	42	51	55		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	7
Chen R		57			Acceptable	not acceptable	Acceptable	Not Acceptable	Acceptable	na	7
Tomlins J		63	73		Acceptable	Acceptable	Acceptable	Not Acceptable	Acceptable	NA	8

70 and above versus less than 70														
	Author	RR	country	region	city	n	publication date	Start	End	recruitment window	FU	study design	clinical setting	Diagnostic modality
Infection	Zhu W	1,1	China	Anhui		116	10-mrt	24-jan	20-feb	27		cohort	Hospital	PCR
	Liu R a	1,75	China	Hubei	Wuhan	4880	7-mrt	22-jan	14-feb	23		cohort	Hospital	PCR
	Shen N	1,56	China	Hubei	Wuhan	5630	30-apr	22-jan	18-feb		27	cohort	Hospital	PCR
	KDC Resp Team	1,36	South Korea			2370					46	cohort	General population	
severe	Zhang J a	2,01	China	Hubei	Wuhan	140	18-feb	16-jan	3-feb	18		cohort	Hospital	PCR
	Qian GQ	11,33	China	Zhejiang		91	17-mrt	20-jan	11-feb	22	27	cohort	Hospital	PCR
	Zhang G a	1,31	China	Hubei	Wuhan	95	26-mrt	16-jan	25-feb	40	46	cohort	Hospital	PCR
	Liu Y	2,35	China		Shanghai	221	28-mei					cohort	Hospital	PCR
	Chen T b	1,06	China	Hubei	Wuhan	203	7-apr	1-jan	10-feb	40	50	cohort	Hospital	PCR
	Lyu P	1,06	China	Henan	Zhengzhou	51	17-apr	15-jan	24-feb	40	40	cohort	Hospital	PCR
	Long L	2,97	China	Hubei	Jingzhou city and Xiangyang city	301	20-apr	16-jan	24-feb	39	45	cohort	Hospital	PCR
ICU	Wang D a	2,11	China		Wuhan	138	7-feb	1-jan	28-jan	27	33	cohort	Hospital	PCR
	Zhang G a	1,87	China	Hubei	Wuhan	95	26-mrt	16-jan	25-feb	40	46	cohort	Hospital	PCR
	Wei J F	4,37	China	Sichuan		103	6-apr	16-jan	10-mrt	54		cohort	Hospital	PCR

	Lyu P	1,3	China	Henan	Zhengzhou	51	17-apr	15-jan	24-feb	40	40	cohort	Hospital	PCR
	Long L	4,61	China	Hubei	Jingzhou city and Xiangyang city	301	20-apr	16-jan	24-feb	39	45	cohort	Hospital	PCR
death														
	Tang N	3,29	China	Hubei	Wuhan	183	18-feb	1-jan	3-feb	33	43	cohort	Hospital	PCR
	Chen T b	6,73	China	Hubei	Wuhan	203	7-apr	1-jan	10-feb	40	50	cohort	Hospital	PCR
	Meng Y	3,78	China	Hubei	Wuhan	168	28-apr	16-jan	4-feb	19	64	cohort	Hospital	PCR
	Nikpouraghdam M	3,94	Iran		Teheran	2968	19-apr	19-feb	15-apr	56	73	cohort	Hospital	PCR
	Richardson S	3,38	US	New York		5700	22-apr	1-mrt	4-apr	34	34	cohort	Hospital	PCR

70 and above versus less than 70					NOS									
Author	% comorbidities	% male	mean age	% BMI > 25	Case definition	Case representativeness	Control selection	control definition	exposure ascertainment	comparable ascertainment	non response rate	overall quality		
Infection														
Zhu W		56	40	23	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	9		
Liu R a		46			Acceptable	Acceptable	Acceptable	Not acceptable	Acceptable	Acceptable	NA	7		
Shen N		47	49		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	acceptable	9		
KDC Resp Team		45			Not Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	7		
severe														
Zhang J a	64	51	57		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	acceptable	8		
Qian GQ		41	50		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	9		
Zhang G a		56	49		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	9		
Liu Y		52			Not acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	8		
Chen T b	42	53	55		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	9		
Lyu P	33	57	54		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	6		
Long L		50	50		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	9		
ICU														

Wang D a	46	54	57		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	9
Zhang G a		56	49		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	9
Wei J F		54	49		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	9
Lyu P	33	57	54		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	6
Long L		50	50		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	9
Death												
Tang N	41	54	54		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	8
Chen T b	42	53	55		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	9
Meng Y	34	51	57		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	8
Nikpouraghdam M	11	66	56		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	9
Richardson S	94	60	63		Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	Acceptable	NA	9